This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1259 entries already.
Under a new partnership, Plectonic Biotech will use Sonrai’s AI-powered multi-omics platform to speed up development of its Logybody cancer treatment technology. The approach aims to cut side effects and improve precision.
The European Commission has scraped a key piece of Green Deal legislation following political shifts within the European Parliament. The move came after Italy, governed by a far-right administration of Georgia Meloni, aligned itself with the European People’s Party (EPP) on the matter.
British gene and cell therapy manufacturing specialist Cellular Origins Ltd has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing.
Cultivated meat is expected to reach price parity with conventional meat sooner than previously forecast, according to a new analysis by technology foresight specialist GetFocus.
Lodz-based CDMO Mabion SA has launched a €500,000 oncology services contest at BIO International Convention 2025, aimed at accelerating the development of recombinant protein-based cancer therapies. The contest will culminate at CPHI Worldwide in Frankfurt this October, spotlighting promising biotechs ready to scale their innovation.
AFYREN’s first biorefinery, AFYREN NEOXY, has reached continuous production, marking a key step toward large-scale commercialisation of its bio-based acids. The plant will now ramp up output and fulfill long-term contracts across key sectors like nutrition, cosmetics, and life sciences. European Biotech News talked to CEO Nicolas Sordet about the long and winding road to sucess.
GEA has launched its second Food Application and Technology Center (ATC) globally in the US, to target the largest consumer market for cellular agriculture. The facility features advanced bioreactors and precision fermentation systems that enable companies to test and optimise processes for producing alternative proteins and other novel food products.
Lose weight without expensive obesity pills? The discovery of a direct link between olfactory receptors and areas of the brain that signal satiety makes this seem possible, initially in mice.
SpliceBio SL has baged US$135m in a Series B financing co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors The Barcelona-based company will use the proceeds to advance SB-007 in Stargardt disease and expand its pipeline of meds that regulate splicing.
Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118.